|
COMMERCE BUSINESS DAILY ISSUE OF MAY 25,1999 PSA#2353Centers for Disease Control and Prevention (CDC), Procurement and
Grants Office, SECTION II, 2920 Brandywine Road, Room 3208, Atlanta, GA
30341-4146 A -- TUBERCULOSIS TRIALS CONSORTIUM (TBTC) SOL 1999N00163 POC Sherry
Smallwood, Contract Specialist, (770) 488-2699 The Centers for Disease
Control and Prevention (CDC) intends to award a multiple-award
contract (approximately 4 -- 6 awards) for the purpose of augmenting
research activities of clinical sites currently implementing the
FDA-approved HIV vaccine trial protocol VAX 004 (BB-IND 7426), "A Phase
III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in
Adults at Risk of Sexually Transmitted HIV-1 Infection in North
America". The Centers for Disease Control and Prevention (CDC) is
interested in (1) obtaining the research data generated from the VAX
004 trial, and (2) conducting additional "sub-studies" (using the
patients enrolled and data generated from the VAX 004 trial) to focus
on other VAX 004 trial-related epidemiologic, laboratory, and
social-behavioral research. The resultant contractors shall be required
to continue implementing the ongoing VAX 004 trial activities as per
the current FDA approved operational guidelines to determine the
protective efficacy of AIDSVAX, and to confirm its safety and
immunogenicity. Furthermore, in the process of carrying out the VAX 004
trial, the contractors will be required to develop additional
trial-related sub-study protocols for research which may include
epidemiologic and laboratory studies of HIV incidence and genetic
characterization of incident HIV infections, social-behavioral research
on risk factors for infection, risk behavior change associated with
trial participation, social harm and discrimination, and
participant/site/community factors related to the successful
implementation of HIV vaccine efficacy trials. These additional studies
will be implemented concurrently and become integrated into trial site
activities supporting the VAX 004 trial implementation. The total
target enrollment for activities under the resultant contracts will be
1000 enrollees (all contract study sites combined), and may include
additional enrollees outside of the trial population for comparative
sub-studies. The awarded contracts shall be of 4 years duration.
Onlywritten requests for copies of the solicitation will be honored.
Written requests may be submitted to the Contract Specialist by fax at
770-488-2671, or by e-mail at svs9@cdc.gov. Telephone requests will
not be accepted. The date specified for receipt of offers will be
approximately 30 days after the solicitation issue date. The
solicitation issue date will be on or about June 11, 1999. Posted
05/21/99 (I-SN334263). (0141) Loren Data Corp. http://www.ld.com (SYN# 0003 19990525\A-0003.SOL)
A - Research and Development Index Page
|
|